HER2现已成为乳腺癌诊疗的有效靶点，但HER2在非小细胞肺癌尤其是肺腺癌中也呈高表达，研究HER2为靶点的肺腺癌诊断、治疗也具有重要意义。在以往研究基础上，本研究构建新型HER2:V2亲和体-培美曲塞分子探针，用放射性核素锝标记该分子探针, 从3种不同HER2表达的肺腺癌细胞和动物模型活体水平研究新型核素锝标记HER2:V2亲和体-培美曲塞分子探针被HER2表达的肺腺癌特异性摄取与体内分布，同时利用Her2:V2亲和体与HER2阳性的肺腺癌细胞受体结合特性将培美曲塞靶向运输至肿瘤部位从而提高化疗药物的疗效，开辟对肺腺癌治疗新途径。新型分子探针既可在活体内分子成像显示HER2阳性肺腺癌细胞的特异摄取，又以可对Her2高表达的肺腺癌的诊断和靶向治疗, 具有创新性。因此，本研究构建新型HER2:V2亲和体-培美曲塞分子探针对肺腺癌的诊断、靶向化疗和疗效评价具有重要意义。

HER2 is now available for effective target for breast cancer treatment, but HER2 in non small cell lung cancer especially in lung adenocarcinoma was also high expression. Therefore, research on HER2 target for lung cancer diagnosis and therapeutic also has an important significance. Based on our previous studies, this research constructs the new HER2:V2 affibody - pemetrexed molecular probe, marking the molecular probe with radionuclide technetium. The specific uptake and biodistribution of the 99mTc- HER2:V2 - pemetrexed molecular probe are studied from 3 different HER2 expression level lung adenocarcinoma cells and animal model in vitro or vivo. At the same time, using Her2:V2 affibody and the HER2 positive lung adenocarcinoma cell receptor targeting binding transport pemetrexed to the tumor site so as to improve the efficacy of chemotherapy drugs on tumor treatment, open up a new way. The new molecular probe can showed specific uptake of HER2 positive pulmonary adenocarcinoma cells in vivo molecular imaging, So realize the HER2 positive lung adenocarcinoma targeting diagnosis and targeting therapy. Therefore, the novel HER2:V2 affibody – pemetrexed molecular probe is of important clinical significance in the targeting diagnosis , targeting chemotherapy and therapeutic evaluation of lung adenocarcinoma.